Targeting peptidylarginine deiminases 2 and 4 in diabetic kidney disease: mechanistic rationale and preclinical evidence.
Many patients with diabetic kidney disease (DKD) continue to progress despite guideline-directed quadruple nephroprotective therapy, driven in part by sterile inflammation that current treatment does not target. Peptidylarginine deiminases 2 and 4 (PAD2/4) are calcium-dependent enzymes that convert peptidyl-arginine to...